This page shows you your search results in order of relevance. This is page number 5.

Order by Relevance | Date

Total 290035 results found since Jan 2013.

Gastrointestinal Stromal Tumours (GIST): A Review of Cases from Nigeria
ConclusionsCharacteristics of GIST in Nigerians are fairly similar to other parts of the world. However, most of our patients present with large masses which are of poor prognostic characteristics.
Source: Journal of Gastrointestinal Cancer - October 27, 2019 Category: Cancer & Oncology Source Type: research

Diagnostic and Therapeutic Challenges in the Management of Acute Massive Overt Bleeding of Jejunal Gastrointestinal Stromal Tumours: Case Series
CONCLUSION: Multiphasic CTA is a single-step diagnostic tool for localisation of bleed and assessment of tumour characteristics in emergent conditions. Surgical resection is the mainstay of treatment for both control of bleed and to provide oncologically clear resection margins.PMID:35199299 | DOI:10.1007/s12029-021-00650-w
Source: Cancer Control - February 24, 2022 Category: Cancer & Oncology Authors: Satish Subbiah Nagaraj Sriram Deivasigamani Amresh Aruni Hemanth Kumar Anurag Sachan Jayanta Samanta Amanjit Bal Source Type: research

Open and minimally invasive surgery for gastrointestinal stromal tumours: a systematic review and network meta-analysis protocol
Introduction Gastrointestinal stromal tumours (GISTs) are the most common mesenchymal tumours of the digestive system, and complete resection is the only way to provide a radical cure for resectable GISTs. Open surgery and minimally invasive approaches, including laparoscopy, robotic surgery and endoscopy, consist of the mainstream GIST resection. However, there is still a lack of evidence regarding which surgical outcomes and long-term prognosis would be better. Thus, we are planning to conduct a network meta-analysis and systematic review aiming to determine the comparative effectiveness among laparotomy, laparoscopy, en...
Source: BMJ Open - February 7, 2022 Category: General Medicine Authors: Mu, M., Cai, Z., Liu, C., Shen, C., Yin, Y., Yin, X., Jiang, Z., Zhao, Z., Zhang, B. Tags: Open access, Gastroenterology and hepatology Source Type: research

Identification of a novel FGFR2-KIAA1217 fusion in oesophageal gastrointestinal stromal tumours: A case report
Conclusion: To the best of our knowledge, this report is the first to describe an FGFR2-KIAA1217 fusion in a patient with a quadruple WT oesophageal GIST. When WT KIT/PDGFRA GISTS are suspected, intensive genetic analysis is recommended, and obtaining a better molecular characterization of these tumours might reveal novel therapeutic avenues.
Source: Frontiers in Oncology - August 1, 2022 Category: Cancer & Oncology Source Type: research

Primary cilia in Gastric Gastrointestinal Stromal Tumours (GISTs): an ultrastructural study
In this study, we report for the first time the presence of primary cilia (PCs) in spindle and epithelioid tumour cells, an ultrastructural feature we consider of special interest that has hitherto been ignored in the literature dealing with the ultrastructure of GISTs. We also point out the frequent occurrence of multivesicular bodies (MVBs). The ultrastructural findings described in gastric GISTs in this study appear to be relevant considering the critical roles played by PCs and MVBs recently demonstrated in tumourigenic processes.
Source: Journal of Cellular and Molecular Medicine - May 15, 2013 Category: Molecular Biology Authors: Tomás Castiella, Guillermo Muñoz, María José Luesma, Sonia Santander, Mario Soriano, Concepción Junquera Tags: Original Article Source Type: research

Systematic review of the side effects associated with tyrosine kinase inhibitors used in the treatment of gastrointestinal stromal tumours on behalf of the EORTC Quality of Life Group
Abstract: Tyrosine kinase inhibitors (TKIs) have revolutionised the treatment of advanced gastrointestinal stromal tumours (GISTs). Imatinib is approved as first line therapy and sunitinib is used in cases of imatinib resistance or intolerance. Compared with conventional treatments, TKIs are delivered over longer periods of time and are more specific in their targets (i.e., molecularly targeted), thus presenting different side effect profiles. We review the safety profiles of imatinib and sunitinib, documenting a total of 95 side effects including patient based as well as medically defined outcomes. Gastrointestinal compla...
Source: Critical Reviews in Oncology Hematology - February 4, 2014 Category: Cancer & Oncology Authors: Samantha C. Sodergren, Alice White, Fabio Efficace, Mirjam Sprangers, Deborah Fitzsimmons, Andrew Bottomley, Colin D. Johnson Source Type: research

Gastrointestinal stromal tumours (GISTs) with a thousand faces: atypical manifestations and causes of misdiagnosis on imaging
Gastrointestinal stromal tumours (GISTs) can lead to emergency situations, such as gastrointestinal bleeding, intestinal obstruction, and tumoural rupture with haemoperitoneum or peritonitis. In addition, if a GIST grows exophytically to a large size, it is often misdiagnosed as a tumour arising from adjacent organs. Sometimes, the atypical appearance of GISTs on imaging causes diagnostic confusion. In this article, we illustrate a variety of GISTs with atypical presentations and also discuss the important diagnostic clues for differentiating GISTs from other lesions.
Source: Clinical Radiology - November 29, 2015 Category: Radiology Authors: S.W. Kim, H.C. Kim, D.M. Yang, K.Y. Won Tags: Pictorial Review Source Type: research

Clinical relevance of integrin alpha 4 in gastrointestinal stromal tumours
Abstract The molecular mechanisms for the dissemination and metastasis of gastrointestinal stromal tumours (GIST) are incompletely understood. The purpose of the study was to investigate the clinical relevance of integrin alpha 4 (ITGA4) expression in GIST. GIST transcriptomes were first compared with transcriptomes of other types of cancer and histologically normal gastrointestinal tract tissue in the MediSapiens in silico database. ITGA4 was identified as an unusually highly expressed gene in GIST. Therefore, the effects of ITGA4 knock‐down and selective integrin alpha 4 beta 1 (VLA‐4) inhibitors on tumour cell proli...
Source: Journal of Cellular and Molecular Medicine - January 29, 2018 Category: Molecular Biology Authors: Olli ‐Pekka Pulkka, John‐Patrick Mpindi, Olli Tynninen, Bengt Nilsson, Olli Kallioniemi, Harri Sihto, Heikki Joensuu Tags: Original Article Source Type: research

Erratum for "Consensus report on the radiological management of patients with gastrointestinal stromal tumours (GIST): recommendations of the German GIST Imaging Working Group".
PMID: 23629916 [PubMed - in process]
Source: Cancer Imaging - May 26, 2013 Category: Radiology Authors: Kalkmann J, Zeile M, Antoch G, Berger F, Diederich S, Dinter D, Fink C, Janka R, Stattaus J Tags: Cancer Imaging Source Type: research

HuR cytoplasmic expression is associated with increased cyclin A expression and inferior disease‐free survival in patients with gastrointestinal stromal tumours (GISTs)
ConclusionsHuR cytoplasmic expression not only correlates with adverse prognosticators and cyclin A overexpression, but also independently predicts worse DFS, indicating a causative role in conferring tumour aggressiveness.
Source: Histopathology - July 26, 2013 Category: Pathology Authors: Yu‐Ching Wei, Fong‐Fu Chou, Chien‐Feng Li, Wei‐Ming Li, Yen‐Yang Chen, Jui Lan, Shau‐Hsuan Li, Fu‐Min Fang, Tsung‐Hui Hu, Shih‐Chen Yu, Hock‐Liew Eng, Yih‐Huei Uen, Yu‐Fang Tian, Jui‐Chu Wang, Hsuan‐Ying Huang Tags: Original Article Source Type: research

MiR-17-92 and miR-221/222 cluster members target KIT and ETV1 in human gastrointestinal stromal tumours
MiR-17-92 and miR-221/222 cluster members target KIT and ETV1 in human gastrointestinal stromal tumours British Journal of Cancer advance online publication, August 22 2013. doi:10.1038/bjc.2013.483 Authors: C M M Gits, P F van Kuijk, M B E Jonkers, A W M Boersma, W F van IJcken, A Wozniak, R Sciot, P Rutkowski, P Schöffski, T Taguchi, R H J Mathijssen, J Verweij, S Sleijfer, M Debiec-Rychter & E A C Wiemer
Source: British Journal of Cancer AOP - August 22, 2013 Category: Cancer & Oncology Authors: C M M GitsP F van KuijkM B E JonkersA W M BoersmaW F van IJckenA WozniakR SciotP RutkowskiP SchöffskiT TaguchiR H J MathijssenJ VerweijS SleijferM Debiec-RychterE A C Wiemer Source Type: research

An overview on molecular biology of KIT/PDGFRA wild type (WT) gastrointestinal stromal tumours (GIST)
Conclusion Large series of patients are required for defining the biological fingerprint of each subtype and integrating it with clinical data. This will allow the transfer of biological information to clinical practice and its use as an additional tool for diagnosis, prognosis and selection of medical treatment.
Source: Journal of Medical Genetics - September 17, 2013 Category: Genetics & Stem Cells Authors: Nannini, M., Biasco, G., Astolfi, A., Pantaleo, M. A. Tags: Immunology (including allergy), Paediatric oncology Review Source Type: research

Phase II study of dovitinib in patients with metastatic and/or unresectable gastrointestinal stromal tumours after failure of imatinib and sunitinib
Phase II study of dovitinib in patients with metastatic and/or unresectable gastrointestinal stromal tumours after failure of imatinib and sunitinib British Journal of Cancer advance online publication, October 1 2013. doi:10.1038/bjc.2013.594 Authors: Y-K Kang, C Yoo, B-Y Ryoo, J J Lee, E Tan, I Park, J H Park, Y J Choi, J Jo, J-S Ryu & M-H Ryu
Source: British Journal of Cancer AOP - October 1, 2013 Category: Cancer & Oncology Authors: Y-K KangC YooB-Y RyooJ J LeeE TanI ParkJ H ParkY J ChoiJ JoJ-S RyuM-H Ryu Source Type: research

The economic impact of cytoreductive surgery and tyrosine kinase inhibitor therapy in the treatment of advanced gastrointestinal stromal tumours: A Markov chain decision analysis
Conclusion: Costs of surgical intervention at different time-points within the treatment course of patients with advanced GIST fluctuate within a relatively narrow range, suggesting that costs arise primarily from the administration of TKI. The decision to pursue cytoreductive surgery should not be based on cost alone. Future studies should incorporate health-state utilities when available.
Source: European Journal of Cancer - November 11, 2013 Category: Cancer & Oncology Authors: Nicole J. Look Hong, Steven L. Chang, Chandrajit P. Raut Tags: Sarcoma Source Type: research

Folate-related polymorphisms in gastrointestinal stromal tumours: susceptibility and correlation with tumour characteristics and clinical outcome
Biasco & Patrizia Hrelia
Source: European Journal of Human Genetics - September 17, 2014 Category: Genetics & Stem Cells Authors: Sabrina AngeliniGloria RavegniniMargherita NanniniJusto Lorenzo BermejoMuriel MustiMaria A PantaleoElena FumagalliNicola VenturoliElena PalassiniNicola ConsoliniPaolo G CasaliGuido BiascoPatrizia Hrelia Source Type: research